30% off. Use code SUMMERSALE30 at checkout for 30% off for 12 months on Plus, Pro and Premium subscriptions. Subscribe now
United States Biotechnology & Medical Research

Palvella Therapeutics Inc (PVLA)

Track

Over the last 90 days, Palvella Therapeutics Inc. has seen a net insider buy of $49,973.5. However, this is primarily driven by a single buy transaction, while significant proposed and planned sales by Officer Kathleen Goin total over $2.5 million. The stock has experienced minimal price change (0.1%) in the past 90 days.
Stock chart
Ticker: PVLA Exchange: NAS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


Subscribe to get access to the transaction volume chart and in-chart transaction details
• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Activity signal Earnings
Top insiders
Trades
Goin Kathleen
Chief Operating Officer
4 sales — total 400,000 USD
Planned sale 17 Jun 2026
Value US$1,798,599.44 | Price 37.72 | Shares 92,768
Planned sale 17 Jun 2026
Value US$4,620,808.95 | Price 206.71 | Shares 7,890
Planned sale 17 Jun 2026
Value US$100,000.00 | Price 110.26 | Shares 1,000
Proposed sale 17 Jun 2026
Value US$100,000.00 | Price 110.73 | Shares 1,000
Planned sale 20 May 2026
Value US$3,325,534.73 | Price 309.62 | Shares 40,948
Planned sale 20 May 2026
Value US$1,575,497.39 | Price 326.84 | Shares 44,525
Planned sale 20 May 2026
Value US$371,094.94 | Price 110.35 | Shares 3,363
Proposed sale 20 May 2026
Value US$475,630.84 | Price 110.56 | Shares 4,302
Planned sale 15 Apr 2026
Value US$13,033.00 | Price 130.33 | Shares 100
Planned sale 15 Apr 2026
Value US$82,539.12 | Price 129.17 | Shares 639
Planned sale 15 Apr 2026
Value US$71,939.78 | Price 128.23 | Shares 561
Planned sale 15 Apr 2026
Value US$190,688.10 | Price 127.13 | Shares 1,500
Planned sale 15 Apr 2026
Value US$189,198.98 | Price 125.96 | Shares 1,502
Proposed sale 15 Apr 2026
Value US$557,238.06 | Price 129.53 | Shares 4,302
Buy 30 Mar 2026
Value US$49,973.50 | Price 112.30 | Shares 445
Planned sale 18 Mar 2026
Value US$36,200.84 | Price 119.08 | Shares 304
Planned sale 18 Mar 2026
Value US$204,776.81 | Price 118.37 | Shares 1,730
Planned sale 18 Mar 2026
Value US$266,633.34 | Price 117.56 | Shares 2,268
Proposed sale 18 Mar 2026
Value US$519,681.00 | Price 120.80 | Shares 4,302
Buy 27 Feb 2026
Value US$300,000.00 | Price 125.00 | Shares 2,400
Buy 27 Feb 2026
Value US$500,000.00 | Price 125.00 | Shares 4,000
Planned sale 18 Feb 2026
Value US$102,035.47 | Price 79.97 | Shares 1,276
Planned sale 18 Feb 2026
Value US$239,528.78 | Price 79.16 | Shares 3,026
Proposed sale 18 Feb 2026
Value US$344,547.00 | Price 80.09 | Shares 4,302
Proposed sale 18 Feb 2026
Value US$344,467.00 | Price 80.09 | Shares 4,301
Planned sale 21 Jan 2026
Value US$367,177.06 | Price 97.94 | Shares 3,749
Planned sale 21 Jan 2026
Value US$52,805.97 | Price 95.49 | Shares 553
Proposed sale 21 Jan 2026
Value US$421,639.02 | Price 98.01 | Shares 4,302
Planned sale 17 Dec 2025
Value US$415,022.54 | Price 96.47 | Shares 4,302
Proposed sale 17 Dec 2025
Value US$416,476.62 | Price 96.81 | Shares 4,302
Planned sale 19 Nov 2025
Value US$242,387.85 | Price 86.51 | Shares 2,802
Planned sale 19 Nov 2025
Value US$128,577.45 | Price 85.72 | Shares 1,500
Proposed sale 19 Nov 2025
Value US$356,807.88 | Price 82.94 | Shares 4,302
Buy 9 Apr 2025
Value US$50,472.30 | Price 20.27 | Shares 2,490
Buy 9 Apr 2025
Value US$50,325.00 | Price 20.13 | Shares 2,500
Buy 18 Dec 2024
Value US$51,720.00 | Price 12.93 | Shares 4,000
Buy 12 Aug 2024
Value US$12,022.98 | Price 15.88 | Shares 757
Buy 12 Aug 2024
Value US$35,624.22 | Price 15.88 | Shares 2,243
Buy 9 Aug 2024
Value US$44,678.70 | Price 14.89 | Shares 3,000
Buy 25 May 2023
Value US$8,500.00 | Price 0.85 | Shares 10,000
Buy 13 May 2022
Value US$10,260.00 | Price 1.71 | Shares 6,000
Sale 30 Aug 2021
Value US$150,380.00 | Price 5.15 | Shares 29,200
Sale 30 Aug 2021
Value US$46,000.00 | Price 5.00 | Shares 9,200
Sale 21 Jul 2020
Value US$5,605,000.00 | Price 2.95 | Shares 1,900,000
Sale 6 Sep 2019
Value US$5,075.32 | Price 4.50 | Shares 1,128
Sale 6 Sep 2019
Value US$115,724.57 | Price 4.50 | Shares 25,720
Sale 6 Sep 2019
Value US$104,170.11 | Price 4.50 | Shares 23,152
Buy 14 Sep 2018
Value US$25,525.00 | Price 5.11 | Shares 5,000
Buy 15 May 2018
Value US$57,500.00 | Price 5.75 | Shares 10,000
Sale 30 Apr 2018
Value US$66,040.00 | Price 6.35 | Shares 10,400
Sale 30 Apr 2018
Value US$6,283,960.00 | Price 6.35 | Shares 989,600
Sale 13 Feb 2018
Value US$673.50 | Price 8.98 | Shares 75
Sale 13 Feb 2018
Value US$70,241.56 | Price 8.98 | Shares 7,822
Sale 3 Jan 2018
Value US$118,540.80 | Price 7.35 | Shares 16,128
Sale 3 Jan 2018
Value US$12,447,166.20 | Price 7.35 | Shares 1,693,492
Sale 18 Dec 2017
Value US$7,934.40 | Price 5.70 | Shares 1,392
Sale 18 Dec 2017
Value US$833,585.10 | Price 5.70 | Shares 146,243
Buy 17 Aug 2017
Value US$48,200.00 | Price 4.82 | Shares 10,000
Buy 17 Aug 2017
Value US$97,800.00 | Price 4.89 | Shares 20,000
Buy 16 Aug 2017
Value US$215,550.00 | Price 4.79 | Shares 45,000
Buy 14 Jun 2016
Value US$13,534.65 | Price 1.71 | Shares 7,915
Buy 13 Jun 2016
Value US$3,502.80 | Price 1.68 | Shares 2,085
Buy 13 Jun 2016
Value US$10,080.00 | Price 1.68 | Shares 6,000
Buy 13 Jun 2016
Value US$8,300.00 | Price 1.66 | Shares 5,000
Buy 6 Jul 2015
Value US$12,971.75 | Price 2.75 | Shares 4,717
Buy 6 Jul 2015
Value US$1,362,028.25 | Price 2.75 | Shares 495,283
Buy 6 Jul 2015
Value US$12,971.75 | Price 2.75 | Shares 4,717
Buy 6 Jul 2015
Value US$1,362,028.25 | Price 2.75 | Shares 495,283
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-06-22 2026-06-17 PlS Planned sale
Goin Kathleen

Chief Operating Officer

Officer
92,768 +11.3%
37.72
US$1,798,599 		92,768 +11.3% 37.72 US$1,798,599
2026-06-22 2026-06-17 PlS Planned sale
Goin Kathleen

Chief Operating Officer

Officer
7,890 +26.9%
206.71
US$4,620,809 		7,890 +26.9% 206.71 US$4,620,809
2026-06-22 2026-06-17 PlS Planned sale
Goin Kathleen

Chief Operating Officer

Officer
73,815 -33.8%
34.20
US$450,444 		73,815 -33.8% 34.20 US$450,444
2026-06-17 2026-06-17 PrS Proposed sale
Goin Kathleen

Officer

Officer
1,000
110.73
US$100,000 		1,000 110.73 US$100,000
2026-05-22 2026-05-20 PlS Planned sale
Goin Kathleen

Chief Operating Officer

Officer
48 -100.0%
111.90
US$5,371 		48 -100.0% 111.90 US$5,371
2026-05-22 2026-05-20 PlS Planned sale
Goin Kathleen

Chief Operating Officer

Officer
891 -94.9%
111.30
US$99,165 		891 -94.9% 111.30 US$99,165
2026-05-22 2026-05-20 PlS Planned sale
Goin Kathleen

Chief Operating Officer

Officer
3,363 -78.2%
110.35
US$371,095 		3,363 -78.2% 110.35 US$371,095
2026-05-20 2026-05-20 PrS Proposed sale
Goin Kathleen

Officer

Officer
4,302
110.56
US$475,631 		4,302 110.56 US$475,631
2026-04-17 2026-04-15 PlS Planned sale
Goin Kathleen

Chief Operating Officer

Officer
100 -100.0%
130.33
US$13,033 		100 -100.0% 130.33 US$13,033
2026-04-17 2026-04-15 PlS Planned sale
Goin Kathleen

Chief Operating Officer

Officer
639 -86.5%
129.17
US$82,539 		639 -86.5% 129.17 US$82,539
2026-04-17 2026-04-15 PlS Planned sale
Goin Kathleen

Chief Operating Officer

Officer
561 -43.2%
128.23
US$71,940 		561 -43.2% 128.23 US$71,940
2026-04-17 2026-04-15 PlS Planned sale
Goin Kathleen

Chief Operating Officer

Officer
1,500 -53.6%
127.13
US$190,688 		1,500 -53.6% 127.13 US$190,688
2026-04-17 2026-04-15 PlS Planned sale
Goin Kathleen

Chief Operating Officer

Officer
1,502 -34.9%
125.96
US$189,199 		1,502 -34.9% 125.96 US$189,199
2026-04-15 2026-04-15 PrS Proposed sale
Goin Kathleen

Officer

Officer
4,302
129.53
US$557,238 		4,302 129.53 US$557,238
2026-04-01 2026-03-30 B Purchase
2.9
JENKINS GEORGE M
Non-Executive Director
445 +0.2%
112.30
US$49,974 		445 +0.2% 112.30 US$49,974
2026-03-20 2026-03-18 PlS Planned sale
Goin Kathleen

Chief Operating Officer

Officer
304 -100.0%
119.08
US$36,201 		304 -100.0% 119.08 US$36,201
2026-03-20 2026-03-18 PlS Planned sale
Goin Kathleen

Chief Operating Officer

Officer
1,730 -85.1%
118.37
US$204,777 		1,730 -85.1% 118.37 US$204,777
2026-03-20 2026-03-18 PlS Planned sale
Goin Kathleen

Chief Operating Officer

Officer
2,268 -52.7%
117.56
US$266,633 		2,268 -52.7% 117.56 US$266,633
2026-03-18 2026-03-18 PrS Proposed sale
Goin Kathleen

Officer

Officer
4,302
120.80
US$519,681 		4,302 120.80 US$519,681
2026-03-02 2026-02-27 B Purchase
2.0
HERON ELAINE J
Non-Executive Director
2,400 +5.3%
125.00
US$300,000 		2,400 +5.3% 125.00 US$300,000
2026-03-02 2026-02-27 B Purchase
2.9
JENKINS GEORGE M
Non-Executive Director
4,000 +2.2%
125.00
US$500,000 		4,000 +2.2% 125.00 US$500,000
2026-02-20 2026-02-18 PlS Planned sale
Goin Kathleen

Chief Operating Officer

Officer
1,276 -100.0%
79.97
US$102,035 		1,276 -100.0% 79.97 US$102,035
2026-02-20 2026-02-18 PlS Planned sale
Goin Kathleen

Chief Operating Officer

Officer
3,026 -70.3%
79.16
US$239,529 		3,026 -70.3% 79.16 US$239,529
2026-02-19 2026-02-18 PrS Proposed sale
Goin Kathleen

Officer

Officer
4,302
80.09
US$344,547 		4,302 80.09 US$344,547
2026-02-18 2026-02-18 PrS Proposed sale
Goin Kathleen

Officer

Officer
4,301
80.09
US$344,467 		4,301 80.09 US$344,467
2026-01-23 2026-01-21 PlS Planned sale
Goin Kathleen

Chief Operating Officer

Officer
3,749 -100.0%
97.94
US$367,177 		3,749 -100.0% 97.94 US$367,177
2026-01-23 2026-01-21 PlS Planned sale
Goin Kathleen

Chief Operating Officer

Officer
553 -12.9%
95.49
US$52,806 		553 -12.9% 95.49 US$52,806
2026-01-21 2026-01-21 PrS Proposed sale
Goin Kathleen

Officer

Officer
4,302
98.01
US$421,639 		4,302 98.01 US$421,639
2025-12-19 2025-12-17 PlS Planned sale
Goin Kathleen

Chief Operating Officer

Officer
4,302 -100.0%
96.47
US$415,023 		4,302 -100.0% 96.47 US$415,023
2025-12-17 2025-12-17 PrS Proposed sale
Goin Kathleen

Officer

Officer
4,302
96.81
US$416,477 		4,302 96.81 US$416,477
2025-11-21 2025-11-19 PlS Planned sale
Goin Kathleen

Chief Operating Officer

Officer
2,802 -100.0%
86.51
US$242,388 		2,802 -100.0% 86.51 US$242,388
2025-11-21 2025-11-19 PlS Planned sale
Goin Kathleen

Chief Operating Officer

Officer
1,500 -34.9%
85.72
US$128,577 		1,500 -34.9% 85.72 US$128,577
2025-11-19 2025-11-19 PrS Proposed sale
Goin Kathleen

Officer

Officer
4,302
82.94
US$356,808 		4,302 82.94 US$356,808
2025-04-10 2025-04-09 B Purchase
2.9
JENKINS GEORGE M
Non-Executive Director
2,490 +22.6%
20.27
US$50,472 		2,490 +22.6% 20.27 US$50,472
2025-04-10 2025-04-09 B Purchase
2.9
JENKINS GEORGE M
Non-Executive Director
2,500 +1.4%
20.13
US$50,325 		2,500 +1.4% 20.13 US$50,325
2024-12-19 2024-12-18 B Purchase
2.9
JENKINS GEORGE M
Non-Executive Director
4,000 +2.3%
12.93
US$51,720 		4,000 +2.3% 12.93 US$51,720
2024-08-12 2024-08-12 B Purchase
4.0
ADAR1 Capital Management, LLC
Large shareholder
757 +5.3%
15.88
US$12,023 		757 +5.3% 15.88 US$12,023
2024-08-12 2024-08-12 B Purchase
4.0
ADAR1 Capital Management, LLC
Large shareholder
2,243 +1.8%
15.88
US$35,624 		2,243 +1.8% 15.88 US$35,624
2024-08-12 2024-08-09 B Purchase
4.0
ADAR1 Capital Management, LLC
Large shareholder
3,000 +2.4%
14.89
US$44,679 		3,000 +2.4% 14.89 US$44,679
2023-05-30 2023-05-25 B Purchase
0.5
KIRITSY CHRISTOPHER P
Non-Executive Director
10,000 +100.0%
0.85
US$8,500 		10,000 +100.0% 0.85 US$8,500
2022-05-16 2022-05-13 B Purchase
0.9
Demuth Tim

Chief Medical Officer

Officer
6,000 +inf%
1.71
US$10,260 		6,000 +inf% 1.71 US$10,260
2021-09-01 2021-08-30 S Sale
2.6
Olwill Shane

Chief Development Officer

Officer
29,200 -86.3%
5.15
US$150,380 		29,200 -86.3% 5.15 US$150,380
2021-09-01 2021-08-30 S Sale
2.6
Olwill Shane

Chief Development Officer

Officer
9,200 -21.4%
5.00
US$46,000 		9,200 -21.4% 5.00 US$46,000
2020-07-22 2020-07-21 S Sale
1.7
Aquilo Capital Management, LLC
Large shareholder
1,900,000 -34.1%
2.95
US$5,605,000 		1,900,000 -34.1% 2.95 US$5,605,000
2019-09-10 2019-09-06 S Sale
4.0
BVF PARTNERS L P/IL
Large shareholder
1,128 -0.4%
4.50
US$5,075 		1,128 -0.4% 4.50 US$5,075
2019-09-10 2019-09-06 S Sale
4.0
BVF PARTNERS L P/IL
Large shareholder
25,720 -1.1%
4.50
US$115,725 		25,720 -1.1% 4.50 US$115,725
2019-09-10 2019-09-06 S Sale
4.0
BVF PARTNERS L P/IL
Large shareholder
23,152 -1.0%
4.50
US$104,170 		23,152 -1.0% 4.50 US$104,170
2018-09-17 2018-09-14 B Purchase KIRITSY CHRISTOPHER P
5,000 +100.0%
5.11
US$25,525 		5,000 +100.0% 5.11 US$25,525
2018-05-16 2018-05-15 B Purchase GERAGHTY JAMES A
10,000 +100.0%
5.75
US$57,500 		10,000 +100.0% 5.75 US$57,500
2018-05-02 2018-04-30 S Sale ORBIMED ADVISORS LLC Large shareholder
10,400 -21.1%
6.35
US$66,040 		10,400 -21.1% 6.35 US$66,040
2018-05-02 2018-04-30 S Sale ORBIMED ADVISORS LLC Large shareholder
989,600 -18.0%
6.35
US$6,283,960 		989,600 -18.0% 6.35 US$6,283,960
2018-02-15 2018-02-13 S Sale ORBIMED ADVISORS LLC Large shareholder
75 -0.2%
8.98
US$674 		75 -0.2% 8.98 US$674
2018-02-15 2018-02-13 S Sale ORBIMED ADVISORS LLC Large shareholder
7,822 -0.1%
8.98
US$70,242 		7,822 -0.1% 8.98 US$70,242
2018-01-04 2018-01-03 S Sale ORBIMED ADVISORS LLC Large shareholder
16,128 -24.7%
7.35
US$118,541 		16,128 -24.7% 7.35 US$118,541
2018-01-04 2018-01-03 S Sale ORBIMED ADVISORS LLC Large shareholder
1,693,492 -23.5%
7.35
US$12,447,166 		1,693,492 -23.5% 7.35 US$12,447,166
2017-12-20 2017-12-18 S Sale ORBIMED ADVISORS LLC Large shareholder
1,392 -2.1%
5.70
US$7,934 		1,392 -2.1% 5.70 US$7,934
2017-12-20 2017-12-18 S Sale ORBIMED ADVISORS LLC Large shareholder
146,243 -2.0%
5.70
US$833,585 		146,243 -2.0% 5.70 US$833,585
2017-08-17 2017-08-17 B Purchase GERAGHTY JAMES A
10,000 +inf%
4.82
US$48,200 		10,000 +inf% 4.82 US$48,200
2017-08-17 2017-08-17 B Purchase Reine Allan

See Remarks
20,000 +44.4%
4.89
US$97,800 		20,000 +44.4% 4.89 US$97,800
2017-08-17 2017-08-16 B Purchase Reine Allan

See Remarks
45,000 +inf%
4.79
US$215,550 		45,000 +inf% 4.79 US$215,550
2016-06-15 2016-06-14 B Purchase Matis Louis

SVP, Chief Development Officer

Officer
7,915 +379.6%
1.71
US$13,535 		7,915 +379.6% 1.71 US$13,535
2016-06-15 2016-06-13 B Purchase Matis Louis

SVP, Chief Development Officer

Officer
2,085 +inf%
1.68
US$3,503 		2,085 +inf% 1.68 US$3,503
2016-06-15 2016-06-13 B Purchase Yoder Stephen S.

President and CEO

Executive Director
6,000 +inf%
1.68
US$10,080 		6,000 +inf% 1.68 US$10,080
2016-06-15 2016-06-13 B Purchase DEPTULA-HICKS DARLENE M

SVP, Chief Financial Officer

Officer
5,000 +inf%
1.66
US$8,300 		5,000 +inf% 1.66 US$8,300
2015-07-08 2015-07-06 B Purchase ORBIMED ADVISORS LLC Non-Executive Director Large shareholder
4,717 +7.8%
2.75
US$12,972 		4,717 +7.8% 2.75 US$12,972
2015-07-08 2015-07-06 B Purchase Khuong Chau Quang Non-Executive Director Large shareholder
4,717 +7.8%
2.75
US$12,972 		4,717 +7.8% 2.75 US$12,972
2015-07-08 2015-07-06 B Purchase ORBIMED ADVISORS LLC Non-Executive Director Large shareholder
495,283 +7.4%
2.75
US$1,362,028 		495,283 +7.4% 2.75 US$1,362,028
2015-07-08 2015-07-06 B Purchase Khuong Chau Quang Non-Executive Director Large shareholder
495,283 +7.4%
2.75
US$1,362,028 		495,283 +7.4% 2.75 US$1,362,028
Explore more

More insider trading research around Palvella Therapeutics Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America